Blockchain Registration Transaction Record

Creative Biolabs Expands In Vivo CAR-T Portfolio with Viral and Non-Viral Options

Creative Biolabs updates in vivo CAR-T development portfolio with viral and non-viral options. Explore flexible solutions for direct immune cell engineering and preclinical research.

This update matters because it provides researchers with more versatile tools to explore in vivo CAR-T development, potentially simplifying the path to more efficient and accessible cancer immunotherapies. By offering both viral and non-viral delivery methods, Creative Biolabs enables scientists to overcome traditional manufacturing hurdles, accelerating the translation of CAR-T therapies from bench to bedside and ultimately benefiting patients who need innovative treatments.